Trending — Top Pharma Rep Posts
Most upvoted anonymous posts from pharmaceutical sales representatives.
Is it ever the right time to leave big pharma for a smaller biotech?
— Pfizer · 88 upvotes
B&L NSM 2026 quota setting — did anyone else leave feeling scammed?
— Bausch Health · 67 upvotes
Novartis routing PTO claims through MetLife now — anyone else hit delays?
— Novartis · 61 upvotes
J&J remapping whole territories March 31 — anyone affected?
— Johnson & Johnson (Janssen) · 52 upvotes
Novo pod restructuring wiping out whole districts — anyone else get the call?
— Novo Nordisk · 47 upvotes
Alnylam comp and culture — honest 2-year review
— Alnylam Pharmaceuticals · 45 upvotes
Opdivo + Yervoy combo — competitive update from the field
— Bristol Myers Squibb · 44 upvotes
Amgen post-Horizon integration still a mess — Tepezza access getting worse
— Amgen · 43 upvotes
Lilly GLP-1 territory — managing demand that exceeds supply
— Eli Lilly · 41 upvotes
Genentech oncology interview breakdown — 5 rounds
— Roche / Genentech · 41 upvotes
GSK respiratory — Nucala vs Fasenra still going strong
— GlaxoSmithKline (GSK) · 40 upvotes
BMS CV reps — are you hearing anything about Q3 headcount decisions?
— Bristol Myers Squibb · 38 upvotes
AbbVie Skyrizi launch in IBD — one year in
— AbbVie · 38 upvotes
Caplyta MDD indication changing my territory completely
— Intra-Cellular Therapies · 35 upvotes
Pfizer oncology comp — negotiation tips from someone who pushed back
— Pfizer · 30 upvotes
Dupixent access in atopic derm — my honest 2026 update
— Sanofi · 27 upvotes
Gilead HIV interview — rejected after 4 rounds
— Gilead Sciences · 27 upvotes
Keytruda expansion — great for science, brutal for reps
— Merck (MSD) · 26 upvotes
AbbVie culture from someone who stayed 8 years
— AbbVie · 25 upvotes
BMS layoffs round 2 — southeast getting cut
— Bristol Myers Squibb · 22 upvotes
Dupixent access still best in class — formulary wins coming
— Regeneron · 22 upvotes
Biktarvy still sells itself — but what happens when generics hit
— Gilead Sciences · 20 upvotes
Tecentriq pullback — what does it mean for our team
— Roche / Genentech · 20 upvotes
Corcept is eating our lunch in Cushing's — anyone else?
— Neurocrine Biosciences · 18 upvotes
Jakafi biosimilar threat — what leadership is telling us vs reality
— Incyte · 17 upvotes
All Posts
·
News